益盛药业(002566) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was CNY 257,252,802.51, representing a 13.69% increase compared to CNY 226,273,733.61 in the same period last year[8] - Net profit attributable to shareholders was CNY 20,356,803.01, up 11.10% from CNY 18,323,123.77 year-on-year[8] - The net profit after deducting non-recurring gains and losses increased by 20.58%, reaching CNY 19,412,334.88 compared to CNY 16,098,693.25 in the previous year[8] - The basic earnings per share for the period was CNY 0.0615, reflecting an increase of 11.01% from CNY 0.0554 in the same period last year[8] - The weighted average return on net assets was 1.12%, up from 1.01% in the previous year[8] - The company expects a net profit attributable to shareholders for the first half of 2018 to increase by 10.00% to 30.00%, estimating between 32.2909 million CNY and 38.1620 million CNY[24] Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 78.20%, amounting to CNY 17,082,514.28, down from CNY 78,349,547.88 in the same period last year[8] - Total assets at the end of the reporting period were CNY 2,656,394,579.10, a slight increase of 0.11% from CNY 2,653,485,977.68 at the end of the previous year[8] - The net assets attributable to shareholders increased by 1.13%, reaching CNY 1,823,270,205.52 compared to CNY 1,802,913,402.51 at the end of the previous year[8] - Accounts receivable decreased by 27.94% to 50.18 million CNY due to the use of notes for equipment and project payments[19] - Prepayments increased by 48.41% to 17.00 million CNY, primarily due to increased payments for cosmetic raw materials[19] - Long-term deferred expenses increased by 40.96% to 1.87 million CNY due to the purchase of property insurance[19] Government Support and Regulatory Compliance - The company received government subsidies amounting to CNY 1,093,689.21, which are closely related to its business operations[9] - The company received a "Food Production License" from the Jilin Provincial Food and Drug Administration, allowing the production of health foods and food products[20] Shareholder and Market Issues - The total number of ordinary shareholders at the end of the reporting period was 27,261[11] - The company plans to reduce the shareholding of certain shareholders to resolve issues related to undisclosed shareholding[15] - The company aims to address the issue of undisclosed shareholding in the shortest time possible while considering the impact on the secondary market[16] Product Performance - The company reported a 381.35% increase in sales revenue for the "消痔灵注射液" product, reaching 13 million CNY compared to the same period last year[21] - Sales revenue for the subsidiary "益盛汉参化妆品有限公司" increased by 18.48%, totaling 69.3753 million CNY[21] Non-Operating Income - The company reported a 99.43% decrease in non-operating income, down to 18,737.36 CNY, due to changes in accounting policies[19]